HeXun Biosciences Co (ROCO:6986) ROCE %: 21.14% (As of Dec. 2025)


ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
23 GF Score
Price NT$47.00
! 1 Warning Sign
View Full Analysis

What is HeXun Biosciences Co ROCE %?

HeXun Biosciences Co ROCO:6986 23 ROCE % is 21.14% as of Dec. 2025. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HeXun Biosciences Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 21.14%.

HeXun Biosciences Co  (ROCO:6986) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

HeXun Biosciences Co ROCE % Related Terms

HeXun Biosciences Co ROCE % Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co ROCE % Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -15.30 -1.06 7.64 27.23 17.80

HeXun Biosciences Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 27.04 27.78 0.00 8.61 21.14
ROCO:6986
23GF Score
HeXun Biosciences Co Ltd ROCO:6986
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeXun Biosciences Co ROCE % Calculation

HeXun Biosciences Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=127.04/( ( (706.919 - 53.755) + (837.065 - 62.544) )/ 2 )
=127.04/( (653.164+774.521)/ 2 )
=127.04/713.8425
=17.80 %

HeXun Biosciences Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=159.792/( ( (792.784 - 55.392) + (837.065 - 62.544) )/ 2 )
=159.792/( ( 737.392 + 774.521 )/ 2 )
=159.792/755.9565
=21.14 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 21.14% mean?
HeXun Biosciences Co (ROCO:6986) has a ROCE % of 21.14% as of Dec. 2025.
Is HeXun Biosciences Co's ROCE % too high?
HeXun Biosciences Co's current ROCE % is 21.14%. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's ROCE % compare to VRTX and REGN?
HeXun Biosciences Co's ROCE % of 21.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. HeXun Biosciences Co's current ROCE % is 21.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current ROCE % of 21.14%. The current ROCE % is 21.14%. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current ROCE % is 21.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score

Get the complete analysis for ROCO:6986

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$47.00
Price